The Translational Research Laboratory in Cardiology has been officially inaugurated. It will be dedicated to conducting research projects focused on antithrombotic therapies for atherothrombotic cardiovascular diseases under the framework of the IISPV
In the province of Tarragona alone, thousands of patients receive antiplatelet therapy each year due to having suffered a cardiovascular atherothrombotic event, such as a myocardial infarction. An important consideration is that not all patients respond equally to these medications — especially P2Y12 receptor inhibitors. Patients who show a diminished response to the drug are at higher risk of experiencing further ischemic events (e.g., heart attacks or strokes), while those with an exaggerated response face an increased risk of bleeding complications. Therefore, it is crucial to conduct research in this area to enable truly personalized therapy, in which the most appropriate drugs, doses, and combinations are selected for each individual patient.
From this perspective, the Cardiology Department of Joan XXIII Hospital has launched the Translational Research Laboratory in Cardiology with the initial aim of investigating antithrombotic treatments for cardiovascular atherothrombotic diseases. Work is already underway to progressively incorporate new research lines focused on various cardiovascular pathologies from a translational approach — that is, research aimed at evaluating how laboratory advances can be applied in clinical practice. The laboratory, currently located in the Biobank area, will be able to perform a range of platelet function tests, which can be complemented by the analysis of genetic polymorphisms. This combination will help assess how patients respond to antithrombotic drugs and support the development of new treatment strategies. This initiative highlights the hospital’s commitment to promoting research, particularly in the field of precision medicine, which seeks to provide more personalized patient care.
As an example of the potential of this research line, it is worth noting that José Luis Ferreiro, Head of the Cardiology Department at the hospital, is one of the authors of a consensus document recently published in JACC: Cardiovascular Interventions — one of the most prestigious journals in the field of cardiology. The document focuses specifically on the standardization and interpretation of antiplatelet drug response, and outlines its main clinical indications for patients undergoing percutaneous coronary intervention. His participation in this document reflects his recognition as an international expert in the field.
Facebook 
Mail 
WhatsApp 
